Mouse Monoclonal Amyloid-beta precursor protein antibody. Suitable for WB and reacts with Synthetic peptide - Human samples. Cited in 10 publications. Immunogen corresponding to Synthetic Peptide within Human APP conjugated to Keyhole Limpet Haemocyanin.
Preservative: 0.09% Sodium azide
Constituents: PBS, Sucrose, 0.25% Polyethylene glycol
WB | |
---|---|
Synthetic peptide - Human | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide - Human | Dilution info 0.1-1 µg/mL | Notes 1 μg/ml for AP / BCIP/ NBT(MTT) detection and 0.1 μg/ml for HRPO / ECL detection. |
Select an associated product type
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis (PubMed:25122912). Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1 (By similarity). By acting as a kinesin I membrane receptor, plays a role in axonal anterograde transport of cargo towards synapses in axons (PubMed:17062754, PubMed:23011729). Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1. Amyloid-beta peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Amyloid-beta protein 42 is a more effective reductant than amyloid-beta protein 40. Amyloid-beta peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. APP42-beta may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts. Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain. The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.
A4, AD1, APP, Amyloid-beta precursor protein, ABPP, APPI, Alzheimer disease amyloid A4 protein homolog, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta (A4) precursor protein, Amyloid-beta A4 protein, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, CVAP, PN-II
Mouse Monoclonal Amyloid-beta precursor protein antibody. Suitable for WB and reacts with Synthetic peptide - Human samples. Cited in 10 publications. Immunogen corresponding to Synthetic Peptide within Human APP conjugated to Keyhole Limpet Haemocyanin.
Preservative: 0.09% Sodium azide
Constituents: PBS, Sucrose, 0.25% Polyethylene glycol
Interacts with the C terminus of beta Amyloid 1-40. Does not cross react with beta Amyloid 1-42.
Thiophilic adsorption and size exclusion chromatography.
Beta Amyloid 1-40 also known as amyloid beta 40 is a peptide predominantly composed of 40 amino acids and it is a major product of amyloid precursor protein (APP) cleavage. Its molecular mass is approximately 4.3 kDa. This peptide is expressed in the brain tissue and cerebrospinal fluid. Beta amyloid engages in forming amyloid plaques which are deposits found most typically in the brain of patients with neurodegenerative conditions.
Small soluble oligomers of beta amyloid interact with neuronal cells leading to synaptic dysfunction and cell death. Beta amyloid 1-40 molecules do not normally function in isolation; they often assemble into beta amyloid plaques a complex structure that can contribute to cellular anomalies. Amyloid beta production and its aggregation play parts in a process that disrupts neural communication impacting memory and learning processes.
The amyloidogenic pathway involves beta amyloid where amyloid precursor protein (APP) is cleaved by beta-secretase and gamma-secretase to generate beta amyloid peptides including amyloid beta 40. This molecule is associated with the oxidation and inflammation pathways where it can interact with other proteins like presenilin. Presenilin is a part of the gamma-secretase complex that influences amyloid production thereby affecting the pathological aggregation process.
Beta amyloid 1-40 is closely linked to Alzheimer's disease a condition marked by cognitive decline and neural loss. The presence of amyloid plaques which are high in amyloid beta content is a characteristic marker of this disease. Furthermore beta amyloid is also associated with cerebral amyloid angiopathy a disorder where the peptide accumulates in the walls of the cerebral blood vessels. In this context tau protein another Alzheimer's-associated protein shows pathological changes influenced by the beta amyloid-induced plaque formation and contributes to neurofibrillary tangles formation.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-beta Amyloid 1-40 antibody [BDI350] (ab20068) at 2 µg/mL
Lane 1: Beta Amyloid peptide 1-40
Lane 2: Beta Amyloid peptide 1-42
Lane 3: Beta Amyloid peptide 1-43
Developed using the ECL technique.
Predicted band size: 86 kDa
Exposure time: 30s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com